Evidence strategy for Medical Technologies and Diagnostics

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/01/eb/01/01eb0117-bd8a-3808-0fc1-54e85d028d9e/mza_5094890008854355116.jpg/600x600bb.jpg

Pharma Market Access Insights - from Petauri Evidence

Petauri Evidence

70 episodes

3 weeks ago

Send us a text In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence) Together, they explore the implications of changing N...

All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Evidence strategy for Medical Technologies and Diagnostics

Pharma Market Access Insights - from Petauri Evidence

53 minutes

1 year ago

Evidence strategy for Medical Technologies and Diagnostics

Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?I...